RxDoctor Payments Data

Brian Crenshaw, MD

Cardiovascular Disease · Greensboro, NCNPI 1093778227

Payments from drug & device makers

$233,982in general payments, 2019–2025

Across 648 payments — averaging $361.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$231K
  • Amgen$723
  • Novartis$518
  • E.r. Squibb & Sons, L.L.C.$321
  • Johnson & Johnson$177
  • Boehringer Ingelheim$168
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,967100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$233,982 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$74,367
Medicare patients
803
Services billed
1,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban860$850,601
VyndamaxTafamidis16$414,930
EntrestoSacubitril/Valsartan243$215,692
XareltoRivaroxaban171$186,713
Repatha SureclickEvolocumab202$186,579
JardianceEmpagliflozin98$91,477
FarxigaDapagliflozin Propanediol82$67,601
Praluent PenAlirocumab65$62,293
Repatha PushtronexEvolocumab18$16,465
NexlizetBempedoic Acid/Ezetimibe18$10,868
Rosuvastatin Calcium676$10,022
Ezetimibe587$9,609
Metoprolol Succinate634$7,413
Atorvastatin Calcium532$5,952
Dofetilide12$5,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$161$1,265,531876 claims
NovartisEntresto$518$215,692243 claims
Johnson & JohnsonXarelto$177$186,713171 claims
Boehringer IngelheimJardiance$168$91,47798 claims
AstraZenecaFarxiga$49$67,60182 claims
Esperion Therapeutics, Inc.Nexlizet$231,018$10,86818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →